An independent review by Aon found that DarioHealth's AI-powered platform for managing chronic conditions can reduce total healthcare costs by 2.5% to 7.2% annually, with potential savings reaching up to 10% when including management of multiple conditions and physician access. For a population of 20,000, this equates to $3.8 million to $10.8 million in yearly savings. The review analyzed 17 studies and real-world data, confirming consistent clinical and financial benefits. This supports DarioHealth's value proposition for employers, health plans, and care organizations aiming to lower costs while improving patient outcomes.
DarioHealth's AI platform is linked to an estimated 2.5% to 7.2% annual reduction in total healthcare costs, with potential savings up to 10% including multi-condition management and physician access. For readers following the health sector, here is Pluang's market snapshot as of Oct 06, 2026 17:51 WIB: out of 100 priced US health stocks, 67 rose and 25 fell. Notable movers include BNGO at USD 1.50 (+3.81%, 99% sell activity), NUWE at USD 0.72 (+3.72%, 76% buy activity), and FLNA at USD 0.90 (+3.45%, 92% buy activity).
Morgan Stanley analyst Bob Huang lowered American International Group's (AIG) price target to $80 from $81, with the stock trading around $76, indicating potential upside. AIG is set to report its Q3 2026 earnings on November 3, with investors focuse...
Vertiv Holdings, a maker of power and cooling equipment for data centers, faces mixed analyst opinions with GLJ Research rating it a "Sell" and BMO Capital giving an "Outperform" rating. Despite a recent stock pullback, the company reported a 241% in...
Apogee Enterprises reported strong fiscal Q2 results with adjusted earnings of $1.17 per share, nearly double the estimated $0.59, and revenue of $391.14 million, surpassing expectations of $362.6 million. This marks a continued trend of beating esti...
McKesson received a bullish price target of $977 from Morgan Stanley, suggesting a 6.7% upside from its current price of $915.45. The company agreed to acquire Option Care Health for $32.05 per share, valuing the deal at approximately $5.8 billion in...
Ameriprise Financial has authorized an additional $5.5 billion for share repurchases through September 2028, supported by $2.1 billion in excess capital and $2.8 billion in liquidity. The company returned $1.9 billion to shareholders in H1 2026, incl...
